Laboratory Co. of America Holdings (NYSE:LH) Stock Holdings Lowered by DF Dent & Co. Inc.

DF Dent & Co. Inc. trimmed its position in Laboratory Co. of America Holdings (NYSE:LH - Free Report) by 38.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,695 shares of the medical research company's stock after selling 1,677 shares during the quarter. DF Dent & Co. Inc.'s holdings in Laboratory Co. of America were worth $618,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in LH. Graney & King LLC acquired a new position in Laboratory Co. of America during the 4th quarter worth about $26,000. Fortitude Family Office LLC increased its holdings in shares of Laboratory Co. of America by 312.5% in the 4th quarter. Fortitude Family Office LLC now owns 132 shares of the medical research company's stock valued at $30,000 after acquiring an additional 100 shares during the last quarter. Geneos Wealth Management Inc. increased its stake in Laboratory Co. of America by 309.8% in the fourth quarter. Geneos Wealth Management Inc. now owns 168 shares of the medical research company's stock valued at $39,000 after purchasing an additional 127 shares during the last quarter. Human Investing LLC acquired a new stake in Laboratory Co. of America during the 4th quarter worth $39,000. Finally, Heck Capital Advisors LLC acquired a new stake in shares of Laboratory Co. of America during the fourth quarter worth about $44,000. 95.94% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on LH shares. StockNews.com raised shares of Laboratory Co. of America from a "hold" rating to a "buy" rating in a report on Sunday. Piper Sandler increased their price objective on Laboratory Co. of America from $240.00 to $260.00 and gave the stock a "neutral" rating in a research report on Monday, February 10th. Citigroup upgraded shares of Laboratory Co. of America from a "neutral" rating to a "buy" rating and lifted their price target for the company from $250.00 to $300.00 in a research report on Tuesday, March 4th. Barclays decreased their price objective on shares of Laboratory Co. of America from $271.00 to $260.00 and set an "equal weight" rating on the stock in a research report on Friday, February 7th. Finally, UBS Group reduced their target price on Laboratory Co. of America from $293.00 to $286.00 and set a "buy" rating on the stock in a research note on Tuesday, January 28th. Three analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $270.38.

Remove Ads

Laboratory Co. of America Trading Up 6.0 %

Shares of LH stock traded up $13.16 on Wednesday, reaching $230.84. 929,253 shares of the stock were exchanged, compared to its average volume of 633,122. The firm has a 50 day moving average of $241.12 and a two-hundred day moving average of $234.80. Laboratory Co. of America Holdings has a 1-year low of $191.97 and a 1-year high of $258.59. The company has a quick ratio of 1.30, a current ratio of 1.44 and a debt-to-equity ratio of 0.67. The stock has a market cap of $19.32 billion, a P/E ratio of 26.17, a price-to-earnings-growth ratio of 1.71 and a beta of 0.99.

Laboratory Co. of America (NYSE:LH - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $3.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.40 by $0.05. Laboratory Co. of America had a net margin of 5.73% and a return on equity of 15.29%. On average, research analysts anticipate that Laboratory Co. of America Holdings will post 16.01 EPS for the current year.

Insider Activity at Laboratory Co. of America

In other news, CMO Amy B. Summy sold 226 shares of the company's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $250.40, for a total value of $56,590.40. Following the sale, the chief marketing officer now owns 4,544 shares in the company, valued at approximately $1,137,817.60. This represents a 4.74 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Adam H. Schechter sold 6,121 shares of the company's stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $244.62, for a total value of $1,497,319.02. Following the sale, the chief executive officer now owns 86,445 shares in the company, valued at $21,146,175.90. The trade was a 6.61 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 14,258 shares of company stock worth $3,518,177. 0.85% of the stock is currently owned by company insiders.

Laboratory Co. of America Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.